Updated on 2024/03/29

写真a

 
OSAWA Mami
 
Organization
Academic Assembly Institute of Medicine and Dentistry Health Sciences Assistant Professor
Faculty of Medicine School of Health Sciences Medical Technology Assistant Professor
Title
Assistant Professor
External link

Degree

  • 博士(医学) ( 2021.3   新潟大学 )

  • 修士(医科学) ( 2015.3   新潟大学 )

  • 学士(保健学) ( 2013.3   新潟大学 )

Research Interests

  • アポトーシス

  • 代償性増殖

  • エクソソーム

  • 臨床化学

  • 脂質

  • 薬剤耐性

Research Areas

  • Life Science / Molecular biology

  • Life Science / Medical biochemistry

Research History (researchmap)

  • Niigata University   Assistant Professor

    2022.4

      More details

  • Niigata Univercity Medical & Dental Hospital   Medical technologist

    2015.4 - 2022.3

      More details

Research History

  • Niigata University   Health Sciences, Institute of Medicine and Dentistry, Academic Assembly   Assistant Professor

    2022.4

  • Niigata University   Medical Technology, School of Health Sciences, Faculty of Medicine   Assistant Professor

    2022.4

Education

  • 新潟大学医歯学総合研究科   分子細胞医学専攻   医学博士

    2016.4 - 2021.3

      More details

  • 新潟大学医歯学総合研究科医科学専攻   医科学専攻   医学修士

    2013.4 - 2015.3

      More details

  • Niigata University   Faculty of Medicine   検査技術科学専攻

    2009.4 - 2013.3

      More details

Professional Memberships

Committee Memberships

  • 一般社団法人新潟県臨床検査技師会   新潟支部幹事 生涯教育  

    2017.4 - 2019.3   

      More details

 

Papers

  • Exosomal p38 Mitogen-activated Protein Kinase Promotes Tumour Repopulation in TP53-mutated Bile Duct Cancer Cells. Reviewed International journal

    Mami Osawa, Yasunobu Matsuda, Jun Sakata, Toshifumi Wakai

    Anticancer research   42 ( 2 )   745 - 757   2022.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Tumour repopulation is a major obstacle for successful cancer treatment. This study investigated whether anticancer agents contribute to tumour repopulation in TP53-mutated bile duct cancer cells. MATERIALS AND METHODS: TP53-mutated HuCCT1 and HuH28 cells were exposed to anticancer agents, and recipient cells were exposed to their conditioned media or exosomes. The effect of inhibitors and siRNA-mediated gene silencing of p38 mitogen-activated protein kinase (MAPK) and of TP53 was analyzed by cell proliferation assays and western blotting. RESULTS: Conditioned media from genotoxic agent-treated cells promoted proliferation of recipient cells (p<0.05), and this effect was abrogated by exosome inhibitors. Exosomes from gemcitabine- or cisplatin-treated cells increased cell proliferation by 1.6- to 2.2-fold (p<0.05) through p38 MAPK signalling. These effects of exosomes were inhibited by inhibition/silencing of p38 MAPK but not by TP53 silencing. CONCLUSION: Exosomal p38 MAPK plays a pivotal role in tumour repopulation in a TP53-independent manner.

    DOI: 10.21873/anticanres.15533

    PubMed

    researchmap

  • Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells. Reviewed International journal

    Mami Osawa, Yasunobu Matsuda, Yoshiaki Kinoshita, Toshifumi Wakai

    Anticancer Research   41 ( 2 )   645 - 660   2021.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Sorafenib is a multikinase inhibitor approved as a first-line therapy for hepatocellular carcinoma. This study examined the sorafenib resistance mechanism. MATERIALS AND METHODS: Hepatoma HepG2 cells were exposed to sorafenib, and the biological activity of the conditioned media was analyzed using cell proliferation/apoptosis assays, multiplex immunoassays, ELISA, and western blot analyses. The effect of urokinase-type plasminogen activator (uPA) inhibitors or siRNA-mediated gene silencing was examined in culture experiments and a mouse xenograft tumor model. RESULTS: Sorafenib increased uPA secretion, which was abrogated by an Akt inhibitor. The growth-inhibitory effect of sorafenib was significantly enhanced by the uPA inhibitors UK122 and amiloride. Sorafenib-induced apoptosis was increased 2.4-fold in uPA siRNA-transduced cells (p<0.05). Combined therapy with sorafenib and amiloride significantly decreased tumor volumes [mean volume: 759 mm3 (sorafenib) vs. 283 mm3 (sorafenib plus amiloride), p<0.05]. CONCLUSION: uPA may play a critical role in sorafenib resistance.

    DOI: 10.21873/anticanres.14816

    PubMed

    researchmap

  • Epidermal growth factor receptor/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens. Reviewed International journal

    Takashi Kobayashi, Masayuki Kubota, Yoshiaki Kinoshita, Yuhki Arai, Toshiyuki Oyama, Naoki Yokota, Koichi Saito, Yasunobu Matsuda, Mami Osawa

    Pediatric Surgery International   35 ( 12 )   1369 - 1378   2019.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To investigate the possibility that the antioxidant stress protein Heme oxygenase-1 (HO-1) is involved in the acquisition of chemoresistance in cisplatin and pirarubicin (CITA) therapy. METHODS: Human hepatoblastoma-derived cell line (HepG2) was used to generate a knockdown cell line of HO-1 by small interfering RNA (siRNA). Expression of HO-1, epidermal growth factor receptor (EGFR), Akt, and extracellular signal-regulated kinase1/2 (ERK1/2) was examined by Western blot. The cytotoxic effect of cisplatin, pirarubicin, and EGFR inhibitor was examined by trypan blue staining. In human hepatoblastoma specimens (n = 5), changes of HO-1 expression were examined immunohistochemically before and after CITA therapy. RESULTS: HO-1 expression in HepG2 cells was increased by the treatment of cisplatin (CDDP) and pirarubicin (THP) dose-dependently. In HO-1 knockdown HepG2 cells, the HO-1 was not expressed and the percentage of trypan blue-positive cells (dead cells) was significantly increased after treatment of CDDP and THP. The EGFR inhibitor decreased the levels of HO-1, phospho-Akt and phospho-ERK1/2 in HepG2 cells. Combination treatment of EGFR inhibitor with CDDP and THP increased the cytotoxic effect in HepG2 cells. In human hepatoblastoma specimens, 4 of the 5 patients (80%) showed HO-1 expression changed much stronger in the viable tumor cells after CITA therapy. CONCLUSION: The cytotoxic effects of CDDP and THP were both enhanced under HO-1 knockdown conditions as well as under conditions that inhibit the activation pathway of HO-1 by EGFR inhibitors. EGFR/HO-1 axis may be involved in acquiring chemoresistance in HepG2 cell lines as well as in human hepatoblastoma.

    DOI: 10.1007/s00383-019-04563-5

    PubMed

    researchmap

  • 肝がん細胞株におけるオーロラキナーゼ阻害剤・ソラフェニブ併用療法の解析 Reviewed

    大澤 まみ, 松田 康伸, 若井 俊文, 廣瀬 雄己, 永橋 昌幸, 坂田 純, 小林 隆, 藤巻 隼, 窪田 正幸

    新潟大学保健学雑誌   12 ( 1 )   57 - 63   2015.9

     More details

    Authorship:Lead author   Language:Japanese   Publisher:新潟大学医学部保健学科  

    【目的】肝細胞癌(肝がん)は、化学療法の効果が乏しい予後不良な悪性疾患である。本研究では、新規の分子標的薬オーロラキナーゼ阻害剤の肝がんに対する作用機序を解析した。【方法】肝がん細胞株HepG2にオーロラキナーゼ阻害剤AZD1152を添加し、細胞シグナルをウエスタン・ブロットで解析した。また分子標的薬ソラフェニブをAZD1152と併用して、アポトーシス誘導率や細胞増殖を観察した。【結果】AZD1152単剤は、がん細胞の増殖は抑制するものの、細胞殺傷効果は認められなかった。AZD1152添加後のがん細胞では、ストレスキナーゼERKが著明に活性化しており、ERK阻害剤やソラフェニブを併用するとアポトーシス細胞数がAZD1152単剤に比べ約20倍に増加した(p<0.01)。【総括】AZD1152は肝がんに対する殺傷効果が極めて弱く、ERK活性化がその原因であることが示唆された。ソラフェニブはERK阻害作用を有しており、有意にオーロラキナーゼ阻害剤の効果を増強した。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2015&ichushi_jid=J06421&link_issn=&doc_id=20160301360007&doc_link_id=http%3A%2F%2Fhdl.handle.net%2F10191%2F38957&url=http%3A%2F%2Fhdl.handle.net%2F10191%2F38957&type=%90V%8A%83%91%E5%8Aw%81F%90V%8A%83%91%E5%8Aw%8Aw%8Fp%83%8A%83%7C%83W%83g%83%8A_Nuar&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F80230_3.gif

  • 代償性増殖 細胞死に伴う細胞調節 の分子機構 Reviewed

    大澤 まみ, 松田 康伸, 若井 俊文, 廣瀬 雄己, 坂田 純, 小林 隆, 藤巻 隼, 窪田 正幸

    新潟大学保健学雑誌   11 ( 1 )   1 - 6   2014.3

     More details

    Authorship:Lead author   Language:Japanese   Publisher:新潟大学医学部保健学科  

    近年、アポトーシス細胞が周囲の細胞に生存・増殖を促す「代償性増殖作用」をもつことが明らかとなったが、そのメカニズムについては未だ不明な点が多い。最近の研究報告により、アポトーシスを進行させる因子であるカスパーゼが、ストレスキナーゼJNKやプロスタグランジンE2を介して、細胞増殖を誘導させる作用を併せ持つことが明らかになった。また酸化ストレスに関与するインターロイキン-11も、代償性増殖に関与する可能性が報告されており、本機構が多彩な因子によって調節されている可能性が推測されている。今後、さらなる研究の発展により、代償性増殖を利用した医療の発展に期待がもたれる。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J06421&link_issn=&doc_id=20140728400001&doc_link_id=http%3A%2F%2Fhdl.handle.net%2F10191%2F38938&url=http%3A%2F%2Fhdl.handle.net%2F10191%2F38938&type=%90V%8A%83%91%E5%8Aw%81F%90V%8A%83%91%E5%8Aw%8Aw%8Fp%83%8A%83%7C%83W%83g%83%8A_Nuar&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F80230_3.gif

  • 非アルコール性脂肪肝炎関連肝細胞がんにおける活性型p70S6キナーゼの解析 Reviewed

    松田 康伸, 若井 俊文, 廣瀬 雄己, 坂田 純, 小林 隆, 大澤 まみ, 藤巻 隼, 窪田 正幸

    新潟大学保健学雑誌   11 ( 1 )   51 - 56   2014.3

     More details

    Language:Japanese   Publisher:新潟大学医学部保健学科  

    【目的】非アルコール性脂肪肝炎(NASH)は、近年急速に増加している原因不明の肝疾患である。本研究では、肝がん治療に有効とされる分子標的薬ラパマイシンの標的シグナルp70S6キナーゼが、NASH肝がんの病態に関与している可能性について検討した。【方法】根治的外科手術療法を施行したNASH肝がん22例の病変組織に対して、リン酸化型(活性型)p70S6キナーゼの免疫組織化学染色を行い、臨床因子・予後の比較検討を行った。【結果】NASH肝がん22例中12例(54.5%)がリン酸化型p70S6キナーゼを高発現しており、組織未分化度と相関した(p=0.047)。リン酸化型P70S6キナーゼ高発現群は、外科切除後3年以内再発率が有意に増加していた(p=0.045)。【総括】p70S6キナーゼを高発現しているNASH肝がんは、再発頻度が高い傾向がある。同シグナルを阻害する分子標的薬ラパマイシンは、本疾患の再発防止に有効である可能性が示唆された。(著者抄録)

    researchmap

    Other Link: https://search.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2014&ichushi_jid=J06421&link_issn=&doc_id=20140728400007&doc_link_id=http%3A%2F%2Fhdl.handle.net%2F10191%2F38939&url=http%3A%2F%2Fhdl.handle.net%2F10191%2F38939&type=%90V%8A%83%91%E5%8Aw%81F%90V%8A%83%91%E5%8Aw%8Aw%8Fp%83%8A%83%7C%83W%83g%83%8A_Nuar&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F80230_3.gif

  • Valproic acid overcomes transforming growth factor-beta-mediated sorafenib resistance in hepatocellular carcinoma Reviewed

    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY   7 ( 4 )   1299 - 1313   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:E-CENTURY PUBLISHING CORP  

    Sorafenib is a multi-kinase inhibitor approved for hepatocellular carcinoma, but rarely causes tumor regression in patients with chronic liver diseases. To investigate whether growth factor-mediated signaling is involved in sorafenib resistance, HepG2 and PLC/PRF/5 hepatoma cells were exposed to epidermal growth factor (EGF), hepatocyte growth factor (HGF) or transforming growth factor-beta (TGF-beta) prior to treatment with sorafenib. Furthermore, to identify an effective combination treatment with sorafenib, growth factor-sensitized cells were treated with sorafenib alone or in combination with celecoxib, lovastatin or valproic acid (VPA). Trypan blue staining and Annexin V assays showed that the cytotoxic effect of sorafenib was inhibited by 15-54% in cells sensitized to TGF-beta (P&lt;0.05). Western blotting analysis showed that TGF-beta significantly activated extracellular signal-regulated kinase (ERK)-mediated AKT signaling, and sorafenib failed to suppress both ERK and AKT in TGF-beta-sensitized cells. The decreased anti-tumor effect of sorafenib was rescued by chemical inhibition of ERK and AKT. When TGF-beta-sensitized cells were treated with sorafenib plus VPA, the levels of phosphorylated ERK and AKT were considerably suppressed and the numbers of dead cells were increased by 3.7-5.7-fold compared with those exposed to sorafenib alone (P&lt;0.05). Moreover, low dose sorafenib-induced cell migration was effectively suppressed by combination treatment with sorafenib and VPA. Collectively, TGF-beta/ERK/AKT signaling might play a critical role in sorafenib resistance in hepatoma cells, and combination treatment with VPA may be effective against this drug resistance.

    Web of Science

    PubMed

    researchmap

  • Hepatitis B virus X stimulates redox signaling through activation of ataxia telangiectasia mutated kinase Reviewed

    Yasunobu Matsuda, Ayumi Sanpei, Toshifumi Wakai, Masayuki Kubota, Mami Osawa, Yuki Hirose, Jun Sakata, Takashi Kobayashi, Shun Fujimaki, Masaaki Takamura, Satoshi Yamagiwa, Masahiko Yano, Shogo Ohkoshi, Yutaka Aoyagi

    International Journal of Clinical and Experimental Pathology   7 ( 5 )   2032 - 2043   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:E-CENTURY PUBLISHING CORP  

    Hepatitis B virus X (HBX) protein plays a crucial role in carcinogenesis, but its mechanism is unclear. The involvement of ataxia telangiectasia mutated (ATM) kinase in the enhanced redox system was investigated by examining the phosphorylation level of ATM in HBX gene-transfected cells and in transgenic mice following redox system manipulation by treatment with hydrogen peroxide (H2O2) or antioxidant. Western blotting and immunostaining showed that phospho-ATM was significantly increased by HBX both in vitro (3.2-fold; p&lt;0.05) and in vivo (4-fold; p&lt;0.05), and this effect was abrogated by antioxidant treatment. The level of PKC-delta in HBX-expressing cells was increased 3.5-fold compared to controls. Nuclear localized NF-E2-related factor 2 (Nrf2) was increased in HBX-expressing cells exposed to H2O2, but remained at lower levels after the treatment with rottlerin, KU55933, or caffeine. The levels of anti-oxidant molecules were increased in HBX expressing cells and in transgenic mice, indicating that HBX stimulates the Nrf2-mediated redox system. The levels of intracellular reactive oxygen species (ROS) were significantly increased in HBX-expressing cells treated with hydrogen peroxide in the presence of ATM inhibitor KU55933 or caffeine. Treatment of HBX-expressing cells with KU55933 or caffeine before the exposure to H2O2 increased the ratio of cell apoptosis to 33 +/- 4% (p&lt;0.05) and 22 +/- 4% (p&lt;0.05), respectively. Collectively, HBX stimulates the ATM-mediated PKC-delta/Nrf2 pathway, and maintains the enhanced activity of the redox system. Therefore, manipulating ATM kinase activity might be a useful strategy for treating HBX-induced carcinogenesis.

    Web of Science

    PubMed

    researchmap

  • Clinical significance of cell cycle inhibitors in hepatocellular carcinoma Reviewed

    Yasunobu Matsuda, Toshifumi Wakai, Masayuki Kubota, Masaaki Takamura, Satoshi Yamagiwa, Yutaka Aoyagi, Mami Osawa, Shun Fujimaki, Ayumi Sanpei, Takuya Genda, Takafumi Ichida

    MEDICAL MOLECULAR MORPHOLOGY   46 ( 4 )   185 - 192   2013.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER JAPAN KK  

    It is well accepted that cell cycle regulators are strongly implicated in the progression of cancer development. p16 and p27 are potent cyclin-dependent kinase (CDK) inhibitors involved in G1 phase progression, and are regarded as adverse prognostic biomarkers for various types of cancers. It has been reported that the main mechanism for p16 inactivation is aberrant DNA methylation, while p27 is exclusively inactivated by proteasome-mediated protein degradation. We have found that p27 is decreased in around half of hepatocellular carcinomas (HCCs), and in some cases p27 is inactivated by inappropriate interaction with cyclin D1/CDK4 complexes. In such cases, p16 is concomitantly inactivated through DNA methylation. Taking into consideration the complex interaction between p16 and p27, a comprehensive analysis including p16 and p27 would be useful for predicting the prognosis of HCC patients.

    DOI: 10.1007/s00795-013-0047-7

    Web of Science

    PubMed

    researchmap

  • p27 Is a Critical Prognostic Biomarker in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma Reviewed

    Yasunobu Matsuda, Toshifumi Wakai, Yuki Hirose, Mami Osawa, Shun Fujimaki, Masayuki Kubota

    International Journal of Molecular Sciences   14 ( 12 )   23499 - 23515   2013.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:MDPI AG  

    Non-alcoholic steatohepatitis (NASH) is a recently identified chronic liver disease, which progresses to liver cirrhosis and hepatocellular carcinoma (HCC). As the number of patients studied to date has been limited, clinically useful prognostic biomarkers of NASH-related HCC have not been available. In this study, we investigated the status of a cell-cycle regulator, p27, in NASH-related HCC. p27 has been regarded as a prognostic factor in various types of cancer patients. A total of 22 cases with NASH-related HCC were analyzed for p27 protein expression, and phosphorylation at threonine 157 (T157) and serine 10 (S10) by immunohistochemical analysis. The correlation of p27 with tumor characteristics, disease-free survival (DFS), and overall survival was analyzed. p27 expression was decreased in 13 HCCs (59%), and was significantly correlated with enlarged tumor size (p = 0.01) and increased cell proliferation (p &lt; 0.01). Phospho-p27 at T157 and S10 was detected in four (18%) and seven (32%) cases, respectively, and patients positive for phospho-p27 (S10) showed reduced DFS (hazard ratio 7.623, p = 0.016) by univariate analysis. Further studies with more patients are required to verify the usefulness of p27 as a biomarker for predicting tumor recurrence in NASH patients.

    DOI: 10.3390/ijms141223499

    Web of Science

    PubMed

    researchmap

  • Effects of rapamycin on granulation formation in response to centrally doubled coiled stents as a tracheal substitute Reviewed

    Masayuki Kubota, Yasunobu Matsuda, Shun Fujimaki, Mami Osawa, Toshifumi Wakai, Kengo Nakaya

    Journal of Pediatric Surgery   48 ( 12 )   2416 - 2424   2013.12

     More details

    Language:English   Publishing type:Research paper (international conference proceedings)  

    Introduction: In experiments involving tracheal wall defects in rabbits, metallic coil stents inevitably induce granulation formation in the defects. We examined the involvement of the mammalian target of rapamycin (mTOR) signaling pathway in granulation formation and examined the effects of rapamycin. Methods: The anterior half of the tracheal wall was removed for a longitudinal length of six tracheal rings. Metallic coils were placed into the tracheal lumen through a wall defect. The rabbits were sacrificed two months after undergoing an endoscopic examination, and the granulation tissue in the tracheal defects was removed for a Western blot analysis and immunohistochemical analysis. Rapamycin (0.5 mg kg- 1 day- 1) was administered three times per week intramuscularly. The data were expressed as the relative expression versus the expression of actin. Results: The level of mTOR phosphorylation in the resected trachea was 0.72 ± 0.45, and it significantly increased in the granulation tissue to 11.6 ± 5.2, with concomitant increases in the phosphorylation levels of p70S6K and S6RP in all five rabbits. Although the systemic administration of rapamycin significantly decreased the levels of phosphorylated mTOR to 4.0 ± 2.4 in the five treated rabbits, the clinical outcomes were unsatisfactory. Three of the five treated rabbits exhibited signs of wound complications, and wet granulation tissue that caused respiratory symptoms was found inside and outside of the coils in four rabbits. Conclusions: Although rapamycin effectively reduced the mTOR activity in the granulation tissue, the granulation formation process seemed to be disturbed, most likely owing to the immunosuppressive effects of rapamycin. © 2013 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.jpedsurg.2013.08.013

    Scopus

    PubMed

    researchmap

  • P21-activated kinase-2 is a critical mediator of transforming growth factor-beta-induced hepatoma cell migration. Reviewed

    Sato Munehiro, Matsuda Yasunobu, Wakai Toshifumi, Kubota Masayuki, Osawa Mami, Fujimaki Shun, Sanpei Ayumi, Takamura Masaaki, Yamagiwa Satoshi, Aoyagi Yutaka

    Journal of Gastroenterology and Hepatology   28 ( 6 )   1047 - 1055   2013.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND AIM: Transforming growth factor-beta (TGF-beta) has been shown to play a central role in the promotion of cell motility, but its functional mechanism has remained unclear. With the aim of investigating the diagnostic and treatment modalities for patients with hepatocellular carcinoma (HCC), the signaling pathway that may contribute to TGF-beta-mediated cell invasion in hepatoma cells was evaluated. METHODS: Three hepatoma cell lines, HepG2, PLC/PRF/5, and HLF, were treated with TGF-beta, and the involvement of the non-canonical TGF-beta pathway was analyzed by cell migration assays. HepG2 cells were treated with a p21-activated kinase-2 (PAK2)-targeting small interfering RNA and analyzed for their cell motility. The relationships between the PAK2 status and the clinicopathological characteristics of 62 HCC patients were also analyzed. RESULTS: The cell migration assays showed that Akt is a critical regulator of TGF-beta-mediated cell migration. Western blotting analyses showed that TGF-beta stimulated Akt and PAK2 in all three hepatoma cell lines, and phosphorylated PAK2 was blocked by Akt inhibitor. Suppression of PAK2 expression by small interfering RNA resulted

    DOI: 10.1111/jgh.12150

    PubMed

    researchmap

  • Mycotoxins are conventional and novel risk biomarkers for hepatocellular carcinoma Reviewed

    Yasunobu Matsuda, Toshifumi Wakai, Masayuki Kubota, Mami Osawa, Ayumi Sanpei, Shun Fujimaki

    WORLD JOURNAL OF GASTROENTEROLOGY   19 ( 17 )   2587 - 2590   2013.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BAISHIDENG PUBLISHING GROUP INC  

    Hepatocellular carcinoma (HCC) is a common malignant disease with poor prognosis. To improve the clinical outcome, early diagnosis of HCC arising from nonviral agents and hepatitis virus is important. Among several etiological factors, mycotoxins defined as carcinogens by the International Agency for Research in Cancer (IARC) might be one of the critical risk factors for nonviral HCC. Aflatoxin B1 is the most well-known carcinogenic mycotoxin for HCC, but the role of the other types of mycotoxin remains unclear. Several studies have reported that a chromatographic separation technique based on high-performance liquid chromatography can successfully detect the concentration of mycotoxins in plasma. Recently, serum level of ochratoxin A (OTA), a widely distributed mycotoxin classified as Group 2B by IARC, was evaluated in HCC patients in Egypt. The results suggested that serum OTA levels might be a good biomarker for HCC. In this article, we review recent studies of OTA, and discuss its possible significance as a biomarker of HCC. (C) 2013 Baishideng. All rights reserved.

    DOI: 10.3748/wjg.v19.i17.2587

    Web of Science

    PubMed

    researchmap

  • DNA damage sensor γ -H2AX is increased in preneoplastic lesions of hepatocellular carcinoma. Reviewed

    Matsuda Y, Wakai T, Kubota M, Osawa M, Takamura M, Yamagiwa S, Aoyagi Y, Sanpei A, Fujimaki S

    TheScientificWorldJournal   2013   597095 - 597095   2013

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Phosphorylated histone H2AX ( gamma -H2AX) is a potential regulator of DNA repair and is a useful tool for detecting DNA damage. To evaluate the clinical usefulness of gamma -H2AX in hepatocellular carcinoma (HCC), we measured the level of gamma -H2AX in HCC, dysplastic nodule, and nontumorous liver diseases. METHODS: The level of gamma -H2AX was measured by immunohistochemistry in fifty-eight HCC, 18 chronic hepatitis, 22 liver cirrhosis, and 19 dysplastic nodules. Appropriate cases were also examined by fluorescence analysis and western blotting. results: All cases with chronic liver disease showed increased levels of gamma -H2AX expression. In 40 (69.9%) of 58 cases with HCC, the labeling index (LI) of gamma -H2AX was above 50% and was inversely correlated with the histological grade. Mean gamma -H2AX LI was the highest in dysplastic nodule (74.1 +/- 22.1%), which was significantly higher than HCC (P &lt; 0.005). Moreover, gamma -H2AX was significantly increased in nontumorous tissues of HCC as compared with liver cirrhosis without HCC (62.5 +/- 24.7%, from 5.1 to 96.0%, P &lt; 0.005). CONCLUSIONS: gamma -H2AX was increased in the preneoplastic lesions of HCC and

    DOI: 10.1155/2013/597095

    PubMed

    researchmap

▶ display all

Books

  • 成分栄養剤のこれまでとこれから : エビデンスからの期待

    諸和樹, 小山諭, 市川寛, 大澤まみ, 若井俊文( Role: Joint author)

    先端医学社  2023.1  ( ISBN:9784865505832

     More details

    Total pages:156p   Language:Japanese

    CiNii Books

    researchmap

MISC

Presentations

  • 乳酸脱水素酵素(LD)活性測定におけるJSCC勧告法とIFCC推奨法の比較 4社の試薬を用いた検討

    大澤 まみ, 松田 将門, 星山 良樹, 成田 一衛

    医療検査と自動化  2020.8 

     More details

  • CK測定における混濁血清処理剤フリーゲンIIの影響の評価 CK低値の血清、血漿検体における検討

    大澤 まみ, 松田 将門, 星山 良樹

    日本医学検査学会抄録集  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 混濁血清処理剤フリーゲンIIを用いた乳び検体のCK測定手順の検討

    大澤 まみ, 松田将門, 星山良樹

    北日本支部医学検査学会  2017.10 

     More details

  • Urokinase-Type Plasminogen Activator/FGF-2 Pathway Is A Critical Target For Sorafenib Resistance In Hepatoma Cells

    大澤 まみ, 松田 康伸, 窪田 正幸, 若井 俊文

    日本癌学会総会記事  2017.9 

     More details

    Language:English  

    researchmap

  • Hepatoma Cells Acquire Sorafenib Resistance through Akt-Fibroblast Growth Factor Signaling)

    大澤 まみ, 松田 康伸, 若井 俊文, 窪田 正幸

    日本癌学会総会記事  2014.9 

     More details

    Language:English  

    researchmap

  • Chemotherapy-Induced Apoptotic Hepatoma Cells Stimulate Compensatory Proliferation

    Mami Osawa, Yasunobu Matsuda, Shun Fujimaki, Toshifumi Wakai, Masayuki Kubota

    21st United European Gastroenterology Week  2013.10 

     More details

  • 肝がん細胞株における抗がん剤誘導性代償性増殖の解析

    大澤 まみ, 松田康伸, 藤巻隼, 若井俊文, 窪田正幸

    日本臨床分子形態学会総会  2013.9 

     More details

▶ display all

Awards

  • Travel grant award

    2013.10   21st United European Gastroenterology Week Berlin 2013   Chemotherapy-Induced Apoptotic Hepatoma Cells Stimulate Compensatory Proliferation

    Mami Osawa, Yasunobu Matsuda, Shun Fujimaki, Wakai Toshifumi, Kubota Masayuki

     More details

Research Projects

  • 細胞外小胞-uPA経路に着目した肝がん腫瘍再増殖の予防法の確立

    2023.4 - 2026.3

    Awarding organization:日本学術振興会 科学研究費助成事業 若手研究

    大澤まみ

      More details

    Authorship:Principal investigator 

    researchmap

  • 「恥ずかしくない学校トイレ」環境の開発~児童ウェル・ビーイングを目指して~

    2022.8 - 2023.3

    Awarding organization:令和4年度 新潟大学U-goグラント

    大澤まみ, 中島伸子, 亀岡雅紀

      More details

    Authorship:Principal investigator 

    researchmap

  • 血清乳びの定量化によるインスリン抵抗性糖尿病の新規検出法の確立

    Grant number:22H04387

    2022.4 - 2023.3

    System name:科学研究費助成事業 奨励研究

    Research category:奨励研究

    Awarding organization:日本学術振興会

    大澤 まみ

      More details

    Grant amount:\410000 ( Direct Cost: \410000 )

    researchmap

  • リポ蛋白リパーゼを用いた新しい乳び検体処理法の開発

    2019.4 - 2020.3

    System name:科学研究費助成事業

    Research category:奨励研究

    Awarding organization:日本学術振興会

    大澤 まみ

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • DNA傷害細胞由来エキソソームを用いた再生治療法の開発

    2014.4 - 2015.3

    System name:医学研究助成金

    Awarding organization:協和会

      More details

 

Teaching Experience

  • 学問の扉 知と方法の最前線

    2023
    Institution name:新潟大学

  • 分析系検査管理論

    2023
    Institution name:新潟大学

  • 卒業研究

    2023
    Institution name:新潟大学

  • 疾病の原因と成り立ち

    2023
    Institution name:新潟大学

  • 人体構造学実習

    2023
    Institution name:新潟大学

  • 血液・腫瘍検査学特論

    2023
    Institution name:新潟大学

  • 臨床生体情報検査科学論

    2023
    Institution name:新潟大学

  • 人体機能構造学I

    2023
    Institution name:新潟大学

  • 医療安全管理学

    2023
    Institution name:新潟大学

  • 医療英語(検査)

    2023
    Institution name:新潟大学

  • 医学検査管理総論

    2022
    Institution name:新潟大学

  • 臨床検査実習

    2022
    Institution name:新潟大学

  • スタディスキルズ (検査)

    2022
    Institution name:新潟大学

  • 血液検査科学実習

    2022
    Institution name:新潟大学

  • 保健学総合

    2022
    Institution name:新潟大学

▶ display all

 

Social Activities

  • 意外と知らない”検査”のお話

    Role(s): Lecturer

    新潟大学大学院保健学研究科 GSH研究実践センター主催 市民公開講座  2022.12

     More details

Academic Activities

  • 実践で活きる精度管理の考え方~不確かさの活用を例に~

    Role(s): Panel moderator, session chair, etc.

    第20回生物試料分析科学会信越支部総会  2022.7

     More details

    Type:Academic society, research group, etc. 

    researchmap